Research Article

Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms

Volume: 6 Number: 3 November 13, 2026
EN TR

Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms

Abstract

Objective: This study aimed to develop and validate simple, sensitive, and cost-effective UV-Visible and first-derivative spectrophotometric methods for the quantitative determination of chlorpromazine in pharmaceutical dosage forms. Methods: The UV-Visible spectrophotometric method was performed at 254 nm, whereas the first-derivative spectrophotometric method was evaluated at wavelengths of 247 nm and 261 nm. Both methods were comprehensively validated according to ICH Q2(R1) guidelines with respect to linearity, accuracy, precision, limit of detection and limit of quantification. Results: Linearity was achieved over the concentration range of 1-25 μg/mL for all proposed procedures. The developed methods demonstrated satisfactory accuracy, with relative error values ranging from -1.87% to 6.64%, and acceptable precision, with relative standard deviation values ranging from 0.04% to 8.64% across intra-day and inter-day evaluations. The limits of detection (LOD) and quantification (LOQ) were calculated as 0.29 μg/mL and 0.89 μg/mL, respectively. The first-derivative spectrophotometric approach provided improved spectral resolution and reduced the influence of potential spectral overlap from formulation components. The validated methods were successfully applied to the determination of chlorpromazine in tablet and ampoule pharmaceutical preparations. Conclusion: The obtained results indicate that the proposed spectrophotometric methods provide rapid, reliable and economical alternatives for routine pharmaceutical quality

Keywords

Supporting Institution

Not applicable

Project Number

Not applicable

Ethical Statement

Not applicable. This study did not involve human participants or experimental animals.

References

  1. 1. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2007;(2):CD000284.
  2. 2. Boyd-Kimball D, Gonczy K, Lewis B, Mason T, Siliko N, Wolfe J. Classics in Chemical Neuroscience: Chlorpromazine. ACS Chem Neurosci. 2019;10(1):79-88.
  3. 3. Mlambo R, Liu J, Wang Q, Tan S, Chen C. Receptors involved in mental disorders and the use of clozapine, chlorpromazine, olanzapine, and aripiprazole to treat mental disorders. Pharmaceuticals (Basel). 2023;16(4):603.
  4. 4. World Health Organization. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2025. World Health Organization; 2025. Accessed August 10, 2026.
  5. 5. Al Shatti LA. Method Development and Validation of Assay of Chlorpromazine Hydrochloride Tablet Formulation Using Ultra Violet Visible Spectrophotometry. J Anal Bioanal Tech. 2014;5(2):1-4.
  6. 6. Schirmer RE. Modern Methods of Pharmaceutical Analysis. Vol 2. 2nd ed. CRC Press; 2024.
  7. 7. Daniel D, Gutz IGR. Spectroelectrochemical determination of chlorpromazine hydrochloride by flow-injection analysis. J Pharm Biomed Anal. 2005;37(2):281-286.
  8. 8. Gruenke LD, Craig JC, Klein FD, et al. Determination of chlorpromazine and its major metabolites by gas chromatography/mass spectrometry: Application to biological fluids. Biol Mass Spectrom. 1985;12(12):707-713.

Details

Primary Language

English

Subjects

Pharmacology and Pharmaceutical Sciences (Other)

Journal Section

Research Article

Publication Date

November 13, 2026

Submission Date

August 19, 2026

Acceptance Date

October 5, 2026

Published in Issue

Year 2026 Volume: 6 Number: 3

APA
Kaya, E. N., & Aşcı, A. (2026). Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms. Pharmata, 6(3), 112-121. https://doi.org/10.62425/pharmata.2021205
AMA
1.Kaya EN, Aşcı A. Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms. Pharmata. 2026;6(3):112-121. doi:10.62425/pharmata.2021205
Chicago
Kaya, Elif Nilay, and Ali Aşcı. 2026. “Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms”. Pharmata 6 (3): 112-21. https://doi.org/10.62425/pharmata.2021205.
EndNote
Kaya EN, Aşcı A (November 13, 2026) Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms. Pharmata 6 3 112–121.
IEEE
[1]E. N. Kaya and A. Aşcı, “Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms”, Pharmata, vol. 6, no. 3, pp. 112–121, Nov. 2026, doi: 10.62425/pharmata.2021205.
ISNAD
Kaya, Elif Nilay - Aşcı, Ali. “Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms”. Pharmata 6/3 (November 13, 2026): 112-121. https://doi.org/10.62425/pharmata.2021205.
JAMA
1.Kaya EN, Aşcı A. Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms. Pharmata. 2026;6:112–121.
MLA
Kaya, Elif Nilay, and Ali Aşcı. “Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms”. Pharmata, vol. 6, no. 3, Nov. 2026, pp. 112-21, doi:10.62425/pharmata.2021205.
Vancouver
1.Elif Nilay Kaya, Ali Aşcı. Development and Validation of UV-Visible and First-Derivative Spectrophotometric Methods for the Determination of Chlorpromazine in Tablet and Ampoule Dosage Forms. Pharmata. 2026 Nov. 13;6(3):112-21. doi:10.62425/pharmata.2021205

Content of this journal is licensed under a Creative Commons Attribution NonCommercial 4.0 International License

29929